Freeze-thaw damage happens at the moving ice front, not at the storage temperature. Once the sample is frozen solid and cold, very little is happening. The damage is done during freezing and thawing, which is why the number of cycles matters and the duration of the hold mostly does not.
Aggregation is the failure mode that reverse-phase HPLC is worst at detecting, because a large soluble aggregate may not elute at all and an insoluble one is filtered out during sample preparation. If your purity result comes back normal but the vial looks hazy, believe the vial. Size-exclusion chromatography is the method that sees this.
Adsorption to the container is a real loss at low concentration. For a peptide at 0.1 mg/mL in an untreated glass vial, single-digit percentage losses to the wall are plausible; at 5 mg/mL it is negligible. This is one of several reasons not to reconstitute to a very dilute working solution and store it.
The Arrhenius relationship underpinning accelerated stability testing is the basis of ICH Q1A, which is why accelerated studies at 40 °C and 75 per cent relative humidity are used to predict shelf life at 25 °C. The same relationship lets you reason about a warm transit lane, with the same caveats about extrapolation.
The caveat is that "within specification" and "unchanged" are different claims. A vial can lose a few per cent of content and still be usable for its purpose while no longer matching its certificate.
Minimise transitions rather than minimising temperature. One freeze and one thaw is fine; five is a different question.
3Small correction: the units in the third paragraph should be micrograms, not milligrams. – RP_C18 7 months ago 2Do you have a reference for the last claim? Not disputing it, just want to read it. – tare_weight 6 months ago add a comment